BioInvent International
Sylvie Ryckebusch in neurobiology from the California Institute of Technology and BSc degrees in physics and mathematics from the University of Maryland, US. Employed since 2022.
Over 20 years of experience in business development, alliance management, and corporate strategy. Sylvie has served in key positions at Serono, Merck KGaA, and Index Ventures as well as McKinsey and Company and the Harvard Business School. Born 1965.
This person is not in any offices
BioInvent International
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively.